PFE Mar 2024 60.000 call
| Previous close | 0.0100 |
| Open | 0.0100 |
| Bid | 0.0000 |
| Ask | 0.0900 |
| Strike | 60.00 |
| Expiry date | 2024-03-15 |
| Day's range | 0.0100 - 0.0100 |
| Contract range | N/A |
| Volume | |
| Open interest | 332 |
Yahoo FinanceAWS expands big pharma partnerships in manufacturing, AI, and R&D
Pfizer and Amazon Web Services are just another example of how artificial intelligence is working in the background in healthcare.
ZacksMerck's (MRK) Pneumococcal Jab Shows Upbeat Responses in Study
Positive data from Merck's (MRK) phase III study on V116, an investigational, 21-valent pneumococcal conjugate vaccine, supports the immunogenicity of V116 compared to standard of care.
GlobeNewswireArvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium
-- Six abstracts have been accepted for presentation, including updated data on vepdegestrant alone and in combination with palbociclib (IBRANCE®) -- NEW HAVEN, Conn. and NEW YORK, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced that updated clinical trial data for vepdegestrant (ARV-471) will be presented at the 2023 San Antonio Breast Cancer Symposium (SABCS). Vepdegestrant is a novel oral PROteolysis TArgeting Chimera (PROTAC®) estrog
